Immunotherapy can be an effective treatment for metastatic cancer, but a significant subpopulation will not respond, likely due to the lack of antigenic mutations or the immune-evasive properties of cancer. Likewise, radiation therapy (RT) is an established cancer treatment, but local failures still occur. Clinical observations suggest that RT may expand the therapeutic reach of immunotherapy. We examine the immunobiologic and clinical rationale for combining RT and immunotherapy, two modalities yet to be used in combination in routine practice. Preclinical data indicate that RT can potentiate the systemic efficacy of immunotherapy, while activation of the innate and adaptive immune system can enhance the local efficacy of RT.
Immunotherapy can be an effective treatment for metastatic cancer, but a significant subpopulation will not respond, likely due to the lack of antigenic mutations or the immune-evasive properties of cancer. Likewise, radiation therapy (RT) is an established cancer treatment, but local failures still occur. Clinical observations suggest that RT may expand the therapeutic reach of immunotherapy. We examine the immunobiologic and clinical rationale for combining RT and immunotherapy, two modalities yet to be used in combination in routine practice. Preclinical data indicate that RT can potentiate the systemic efficacy of immunotherapy, while activation of the innate and adaptive immune system can enhance the local efficacy of RT.

Introduction
Over the past two decades, scientific and technological advances in immunotherapy have contributed to its role as one of the more promising cancer treatments. Previously, immunotherapy had been limited to nontargeted agents such as the Bacillus Calmette-Guerin vaccine, IL-2, and interferon-γ, but the characterization of cancer-specific antigens allowed for the emergence of cancer vaccines and cell-based therapies. In addition, immunobiologists identified checkpoints in immune regulation that led to the development of molecularly targeted approaches in cancer immunotherapy.

Although immunotherapy is enticing because of occasional profound responses, it presently benefits a minority of patients in limited disease sites, and responses can be short lived. New combination approaches are needed to increase the efficacy of immunotherapy and expand its reach to other malignancies. Herein we describe the shortcomings of each immunotherapeutic modality. We then describe how radiation therapy (RT) counters immune evasion and how immunotherapy may potentiate local effects of RT. We also address the logistical aspects of combining RT with immunotherapy and discuss ongoing and future clinical applications.

Immunotherapy: principles and shortcomings
Mechanisms of tumor immune evasion. Immunotherapy emerged from the basic tenet of tumor immunology that tumors harbor antigens recognized by the immune system (1). This is supported by the observation of concomitant immunity, wherein a host bearing a progressive tumor will reject an inoculum of the same tumor at a distant site (2, 3).

The inability of immunotherapy to achieve maximal efficacy is related to immune-evasive properties of tumor cells. Broadly, tumor cells can either decrease their intrinsic immunogenicity or induce tolerance through interactions with the immune system. This tumor-host immune relationship is encompassed by the cancer immunoediting hypothesis, which states that tumors can be both held in check and promoted by the immune system (Figure 1 and refs. 4, 5). Cancer immunoediting can be described by three phases: elimination, equilibrium, and escape. In the elimination phase, transformed cells are quickly recognized and destroyed. We now know that tumors that are not eliminated are “sculpted” by the immune environment in which they develop (4). This tumor-host relationship defines the equilibrium state, until the balance of tumor growth and immune regulation tips and tumor escape prevails. The clinical presence of a tumor suggests a failure in elimination and progression to equilibrium or escape. Immunotherapy aims to shift the tumor from the equilibrium and escape phases to the elimination phase. The examples below illustrate how tumors avoid immunotherapy-mediated elimination.

Vaccine-based strategies. Two studies examined the use of vaccines in metastatic castrate-resistant prostate cancer. In a randomized, phase 3 study from 2006, investigators examined Provenge, a dendritic cell vaccine consisting of peripheral blood mononuclear cells enriched with GM-CSF and prostatic acid phosphatase, a tumor antigen (6). The study randomized 512 patients to the vaccine or a similar product lacking tumor antigen and observed a 4-month benefit in overall survival after 3 years (but no change in progression-free survival). In 2010, a randomized, phase 2 study of poxviral-based prostate cancer vaccine in 112 participants (82 patients, 40 control subjects) demonstrated a median survival increase of 8.5 months and an increase in 3-year overall survival from 18% to 30% (7). Most recently, tumor-associated peptide (TUMAP) vaccines have shown a survival benefit in renal cell carcinoma (8).

Cancer vaccine therapy has achieved partial success by modulating a preexisting response to tumor antigens or inducing new antitumor responses. As described above, cancer vaccines appear to affect overall survival more than they mediate objective responses. Although this could be due to the inability of current imaging modalities to distinguish antitumor inflammatory responses from persistent tumors, a more likely explanation is a shift in the immune system from the escape phase to the equilibrium phase, but not to the elimination phase. This failure of elimination can be attributed to the persistence of negative regulatory checkpoints, incomplete amplification of an effector T cell population, or vaccination against an insufficient variety of antigens. Moreover, persistent exposure of antigen without appropriate costimulation can induce peripheral T cell tolerance and apoptosis (9).

Delivering effector cells. In the 1980s, tumor-infiltrating lymphocytes were isolated, expanded, and used therapeutically in metastatic melanoma (10). Unlike cancer vaccines, which indirectly amplify the effector component of immunity, this approach
directly contributes an effector population of cells. In a study of 93 patients, response rates by RECIST ranged from 49%–72%; 22% had a complete response (11).

By 2006, human peripheral lymphocytes had been engineered with tumor specificity using a TCR, and a study demonstrated efficacy when these lymphocytes were administered to patients with metastatic melanoma (12). A sister approach uses chimeric antigen receptors (CARs), a fusion between the antigen-binding (variable) portion of an antibody and the signaling component of a TCR. Over the past decade, TCR-based adoptive immunotherapy has successfully treated patients with melanoma and synovial cell sarcoma (13). Adoptive immunotherapy using CARs has been effective in neuroblastoma, and more recently, success was reported using CD19-specific CARs in advanced follicular lymphoma, refractory chronic lymphocytic leukemia, and pediatric acute lymphocytic leukemia (14–17). These profound responses occur in a subset of patients; the challenge of ongoing clinical trials using CARs is to increase the number of complete and durable responses. This promising approach is rapidly being developed in a variety of solid tumors, including prostate cancer, non–small cell lung cancer, glioblastoma, and breast and ovarian cancer.

In terms of cancer immunoediting, delivering effector T cells is akin to adding an immune component capable of elimination. The presence of natural “off” switches in the immune system counteracts the systemic activation of T cells. Peripheral T cells can be induced into anergy or exhaustion, as they would in autoimmunity and chronic viral infection, respectively (18). As a result, T cells may express predominantly negative regulatory receptors when they arrive at distant tumor sites. As T cells repeatedly encounter antigens, they proceed down a differentiation sequence from naive to central and effector memory that correlates with decreased proliferation, cytokine release, and antitumor function (19). Thus, the immune escape state prevails.

**Targeted immunotherapeutics.** Molecular therapeutics (e.g., monoclonal antibodies) can shift the immune system toward antitumor activity by manipulating immune checkpoints. The most successful therapy thus far has been ipilimumab (Figure 2), a fully human monoclonal antibody that inhibits CTLA4, a negative regulatory molecule that inhibits function of the immune system (20). The rationale is to trigger preexisting antitumor immune responses that are lying dormant.

In a phase 3 study of 676 metastatic melanoma patients that compared the efficacy of ipilimumab, gp100 peptide vaccine, or...
their combination, the median survival of patients receiving ipilimumab alone or in combination with the vaccine was four months longer than patients receiving the vaccine alone (21). A subsequent phase 3 clinical trial combining ipilimumab with standard chemotherapy showed a clear improvement in both overall and progression-free survival compared with standard chemotherapy alone (22). Ipilimumab is currently being studied in cancers of the prostate (in combination with vaccine therapy) (23), cervix, pancreas, lung, ovary, bladder, and breast.

Several other molecules and pathways act as immune switches. Most recently, clinicians have targeted PD-1, another negative regulatory receptor expressed on T cells. This phase 2 trial enrolled patients with 5 different solid tumors and observed 20%–25% objective responses in melanoma, renal cell carcinoma, and non-small cell lung cancer (24). It is unknown why a response was observed in lung cancer, but the mechanism may relate to the high number of mutations compared with other epithelial malignancies. In any case, since the treatment was effective in only a minority of patients, these effects may be bolstered by the addition of RT.

Switching a single immune checkpoint may be insufficient to induce an antitumor response and may explain some of the failures of targeting single immune regulatory checkpoints like PD-1 or CTLA4. Tumors already in immune escape are less likely to benefit from activation of a single immune checkpoint, as other factors such as poor antigenicity and additional negative immune regulators predominate. Tumors on the border between equilibrium and elimination states may be more likely to respond.

Another challenge is the maximum tolerated immune activation. Although agents such as ipilimumab alter tumor microenvironments, our choices of immunotherapeutics and adjuvants such as RT are mitigated by concern for “on-target” toxicity concerns. These side effects, which are due to an immune response against appropriate healthy targets, have been reported in immunotherapy (including ipilimumab) (22) and may limit the simultaneous targeting of multiple immune regulatory pathways.

Immunomodulatory properties of RT

The term abscopal, deriving from the Latin abscopus (target) was introduced in 1953 (25) to describe a rare phenomenon in which the effects of RT are seen outside of the treated area. Anecdotally, tumors outside of RT treatment fields have been said to shrink as a result of a putative systemic inflammatory or immune response provoked by RT (26–28). In contrast, others described RT as an immunosuppressor (29). Lymphocytes are exquisitely sensitive to the effects of RT (30–32), and irradiating the tumor target could potentially eliminate antitumor immune activity. This, along with the general ineffectiveness of RT on local control and of early immunotherapies on systemic disease, dampened enthusiasm for pursuing the combination.

In 2012, two case reports highlighted the immunoadjuvant effect of RT in melanoma, which was classically thought to be an immunogenic tumor (33, 34). Following RT, preexisting tumor-specific antibody levels rose, T cell activation markers were enriched, and new antitumor antibodies were identified. In one case, the patient had a presumed abscopal response after RT alone and a second response after combined RT and targeted immunotherapy. In the second case, the patient progressed slowly despite treatment with targeted immunotherapy, but then exhibited a response after palliative radiotherapy and additional treatment with targeted immunotherapy. These initial anecdotal reports focused on the potential for radiation to spark a systemic antitumor immune response. Augmenting immune activity may also potentiate the local effects of RT. The possibility of improving treatment of both local and widespread disease makes this combination worthy of closer examination.

How RT counters immune evasion

Antigen quantity, variety, and presentation. What can be done to encourage this reverse transition from escape to equilibrium to elimination? Results from phase 1 and 2 vaccine studies of HLA-restricted multiple TUMAP vaccines in renal cell carcinoma suggest that robustness of antitumor response to vaccines correlates with the number of antigens to which the immune system mounts a response (35). The genomic complexity of malignancies, highlighted by numerous somatic mutations (36), is a source of numerous “private” antigens not otherwise expressed in normal tissue (37). In vitro and in vivo mouse studies indicate that tumor irradiation exposes this complex antigenic environment by generating new peptides and increasing the pool of intracellular peptides for cross-presentation (38, 39). It is conceivable that without the generation of these new antigens by RT, the persistent tolerogenic antigens are most expressed, impeding the antitumor immune response.

Tumors also evade antigen presentation. Expression of MHC-I molecules, critical for antigen recognition by cognate CD8+ TCRs, is diminished in tumors. This has been especially well documented in breast, prostate, and lung cancer (40). Tumors can also lose the ability to process antigens intracellularly or can select for less antigenic clones. Radiation, on the other hand, augments MHC-I expression (38, 39, 41). Although dendritic cells have been shown to naturally infiltrate certain tumors, including melanoma and cancers of the breast, stomach, thyroid, and prostate (42), ablative RT doses can recruit hematopoietic and dendritic cells into tumor (43). However, the recruitment of dendritic cells can actually inhibit the adaptive immune response and promote tumor growth (44, 45). Preexisting suppressive dendritic cells in draining lymph nodes can disrupt T cell proliferation at these sites. Likewise, the tumor microenvironment can suppress dendritic cell activity. For example, constituent transcription factor activation (e.g., STAT3) in tumors leads to cytokine release (e.g., TGF-β, VEGF, adenosine), inhibiting maturation of APCs and contributing to tumor evasion (46, 47).

Bridging innate and adaptive immunity. Immunotherapy often seems to fail due to an inability to transition from equilibrium to elimination phase. Radiation establishes a mechanistic link between an innate and adaptive immune response that may overcome this failure. TLR4 has been shown to play a central role in this link in animal models (Figure 2 and ref. 48). Apetoh et al. demonstrated that RT causes dying tumor cells to release high-mobility group box 1 (HMGB-1), a well-described “danger signal” that binds TLR4 (48). Tumor antigen processing and presentation on MHC-I molecules is dependent on the HMGB-1/TLR4 interaction. Mice lacking this pathway could not be successfully vaccinated against tumors, and RT was not effective in treating these tumors. These results are supported by a study combining RT and a different TLR, TLR7, in a mouse model of lymphoma. Compared with either treatment alone, combination therapy improved survival in a CD8+ T cell–dependent manner (49).

The identification of TLR4 as a link between innate and adaptive immunity after radiotherapy was fueled by clinical observations. Node-positive breast cancer patients with inactivating
TLR4 mutations have a worse prognosis after chemoradiation than those without the mutation (50). A similar observation was noted in patients with head and neck squamous cell carcinomas who bear these mutations (51). More fundamentally, in a series of esophageal squamous cell carcinoma patients, preoperative chemoradiation increased cancer-specific T cell responses and serum levels of HMGB-1, the latter of which correlated with overall survival. Again, this suggests a link between innate and adaptive responses (52).

Inducing a T cell response. The most recent and promising immunotherapeutics shift the tumor microenvironment in favor of T cell activation by blocking negative inhibitory molecules (CTLA4, PD-1, TIM3, LAG3) and stromal cells (myeloid-derived suppressor cells [MDSCs]) (Figure 2 and ref. 53). Cell-based immunotherapies bypass the initial activation step altogether via adoptive transfer of ex vivo activated tumor-specific lymphocytes, which are typically equipped with costimulatory molecules. However, even these lymphocytes can be negatively regulated and nudged toward tolerance once they arrive in the tumor microenvironment. By inducing the release of danger signals such as HMGB-1, radiation can putatively promote activation and maturation of APCs and help shift the balance toward T cell activation (Figure 2 and ref. 54). In support of this, naïve T cells in draining lymph nodes of tumors irradiated with ablative doses proliferate to a far greater degree than in lymph nodes of nonirradiated tumors (55).

The development of a systemic antitumor immune response has been described as concomitant immunity. For example, in a murine model of concomitant immunity wherein mice harbored immunogenic primary tumors, tumor challenge at a distant site was rejected, apparently via mediation by effector CD8+ T cells and regulatory CD4+CD25+ T cells (2). RT, likewise, may induce concomitant immunity where it previously did not exist (e.g., RT-induced in situ vaccination). In an animal model of breast cancer, ablative RT of a primary tumor prevented the growth of metastatic tumor colonies in the lung, an effect that was dependent on the presence of CD8+ T cells (55). Other animal models have displayed augmentation of systemic antitumor immunity following local RT, with reduction, control, or elimination of distant metastases, especially in combination with immunotherapy (55–63). As a result, the combination of RT and immunotherapy in locally advanced disease is now being studied in clinical trials (Table 1).

In addition to promoting tumor recognition by preexisting tumor-specific T cells, RT can also generate tumor-specific cytotoxic T cells (64). Cytotoxic T cells are more easily recruited to the irradiated tumor site due to the release of chemokines such as CXCL16, as demonstrated in breast cancer cells (ref. 65 and Figure 2). Irradiated tumors upregulate death receptors (e.g., FAS), promoting the cytotoxic effect of T cells at the tumor site (66). The immune system, unleashed of its negative regulatory pathways at the site of the irradiated tumor, is a powerful antitumor agent locally. These studies suggest a role for immunomodulatory agents in promoting improved RT efficacy.

In fact, an intact immune system may be critical for RT to exert its maximal antitumor effect. In a mouse model of melanoma, high-dose, single-fraction RT slowed the growth of small tumors in immunocompetent mice, but not in nude mice. Investigators demon-
<table>
<thead>
<tr>
<th>ClinicalTrials.gov identifier</th>
<th>Disease site</th>
<th>Design</th>
<th>Primary outcome measure</th>
<th>Phase</th>
<th>Disease site</th>
<th>Disease site</th>
<th>RT</th>
<th>Immunotherapy</th>
<th>RT Treatment timing</th>
<th>Treatment timing</th>
<th>Primary outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01449279</td>
<td>Melanoma</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>1</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT &lt; 2 days after ipilimumab</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01689974</td>
<td>Melanoma</td>
<td>2 arms, randomized: ipilimumab prior to RT or ipilimumab alone</td>
<td>Tumor response</td>
<td>2</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01557114</td>
<td>Melanoma</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Maximum tolerated dose</td>
<td>1</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01565837</td>
<td>Melanoma</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>2</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Toxity</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01497808</td>
<td>Melanoma</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Safety</td>
<td>1</td>
<td>2 arms, randomized: RT alone vs. RT plus immunotherapy</td>
<td>Tumor response</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT00861614</td>
<td>Prostate</td>
<td>2 arms, randomized: RT alone vs. RT plus SRT</td>
<td>Overall response</td>
<td>2</td>
<td>1 arm: ipilimumab prior to RT</td>
<td>Immune response</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01347034</td>
<td>Soft tissue sarcomas</td>
<td>2 arms, randomized: RT alone vs. RT plus dendritic cell therapy</td>
<td>Immune response</td>
<td>2</td>
<td>2 arms, randomized: RT alone vs. SRT</td>
<td>Overall response</td>
<td>Ipilimumab</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Ipilimumab</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>NCT01421017</td>
<td>Breast cancer</td>
<td>1 arm: imiquimod plus RT to select skin metastases</td>
<td>Tumor response</td>
<td>1</td>
<td>1 arm: imiquimod plus RT to select skin metastases</td>
<td>Immune response</td>
<td>Imiquimod</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Imiquimod</td>
<td>Imiquimod</td>
</tr>
<tr>
<td>NCT00751270</td>
<td>Supratentorial malignant glioma</td>
<td>1 arm: surgical resection with Adv-k injection, and then RT or Adv-k injection into tumor bed</td>
<td>Safety: immune response</td>
<td>1</td>
<td>2 arms, randomized: placebo vs. RT with Adv-k injection</td>
<td>Toxicity</td>
<td>Adv-k injection</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Adv-k injection</td>
<td>Adv-k injection</td>
</tr>
<tr>
<td>NCT01595321</td>
<td>Pancreatic cancer (stage R0)</td>
<td>1 arm: cyclophosphamide, vaccine, SRT, and FOLFIRINOX</td>
<td>Disease-free survival</td>
<td>3</td>
<td>1 arm: surgical resection with RT followed by pro-drug therapy (valacyclovir) and RT</td>
<td>Toxicity</td>
<td>Adv-k injection</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Adv-k injection</td>
<td>Adv-k injection</td>
</tr>
<tr>
<td>NCT01436968</td>
<td>Prostate cancer, localized, intermediate, or high risk</td>
<td>2 arms, double-blind, randomized: Adv-k vs. placebo followed by RT with or without androgen deprivation therapy</td>
<td>Disease-free survival</td>
<td>3</td>
<td>2 arms, double-blind, randomized: Adv-k vs. placebo followed by RT with or without androgen deprivation therapy</td>
<td>Toxicity</td>
<td>Adv-k injection</td>
<td>Palliative</td>
<td>RT from week 4 to week 10 of ipilimumab, before week 6 ipilimumab</td>
<td>Adv-k injection</td>
<td>Adv-k injection</td>
</tr>
</tbody>
</table>
strated that CD8+ T cells were necessary for this slowed growth and improved survival of immunocompetent mice after RT (55, 64). A more recent study in a mouse model of intracranial glioma demonstrated that combining RT and anti–PD-1 antibody prolonged survival—an effect that was not seen with either modality alone and that was abrogated by depletion of CD4+ or CD8+ T cells (41).

Clinical trials of combination RT and immunotherapy

The enthusiasm for the combined approach of RT and immunotherapy has led to clinical trials (Table 1). In particular, the FDA approval of ipilimumab for use in metastatic melanoma has led to the design of phase 1 and 2 trials that combined ipilimumab treatment with RT, most of which will primarily assess safety and early efficacy. The most informative of the studies combining RT and ipilimumab may be a two-arm study examining the benefit of adding RT to ipilimumab (ClinicalTrials.gov identifier: NCT01689974). It will be difficult to assess the contribution of RT to systemic immune response or efficacy in single-arm combination studies.

Other current trials are exploring dendritic cell vaccination (both intratumoral and systemic) in combination with RT, and 1 trial is studying the use of topical immunotherapy together with RT in breast cancer skin metastases. RT in all trials is delivered using conventionally fractionated regimens or stereotactic techniques. For adoptive cell transfer therapy, local immunoadjuvant RT techniques (not including whole body irradiation as an immunodepleting regimen) have not yet been studied in humans but are ripe for research.

The combination of RT and immunotherapy has proven to be safe in a controlled setting. In a phase 1 study of 12 patients, investigators demonstrated the safety of combining stereotactic body RT and interleukin-2, an FDA-approved immunotherapy for metastatic renal cell carcinoma and melanoma (67). Furthermore, response rates compared favorably with historical data on IL-2 alone, and responding patients exhibited characteristic T cell populations in peripheral blood prior to treatment. A similar single-arm phase 1/2 study also demonstrated safety and feasibility of combining local RT with a TLR9 agonist (68).

As phase 2 studies report early results, a critical appraisal of clinical response rates is needed. Current imaging modalities may be unable to distinguish between inflammation induced by RT or immunotherapy and persistent disease. Early reports will not include survival data, but immune correlative studies that include peripheral blood examination for cytokine levels, antigen-specific T cell responses, and phenotypes of immune cells, as well as pathologic evidence of antitumor immunity, will be essential. Many of the studies listed in Table 1 plan to examine peripheral markers of immune activation.

To understand the pathologic changes in the tumor microenvironment, studies of RT and immunotherapy should be considered in the preoperative setting. One such investigation is underway for soft tissue sarcomas (ClinicalTrials.gov identifier: NCT01347034). In this two-arm study, conventionally fractionated RT is followed by autologous dendritic cells administered prior to surgical resection. However, in accordance with standards of care, the experimental therapy in this study is dendritic cells rather than RT. In addition to soft tissue sarcomas, other sites prime for clinicopathologic studies, given the routine use of preoperative RT, are rectal and esophageal cancers as well as head and neck and lung malignancies that require salvage surgery after chemoradiation.

While the majority of the studies listed in Table 1 are designed for the metastatic setting, there may be a unique therapeutic window in locally advanced disease. In this setting, preoperative or definitive RT in combination with immunotherapy may induce in situ vaccination against micrometastatic disease as a clinical model for concomitant immunity. In locally advanced tumors that have a high propensity for metastasis, such an approach may improve distant metastasis-free survival.

One challenge is finding a place for the combination of RT and immunotherapy in the context of current standards of care. For instance, one study in pancreatic cancer will examine the safety of a cancer vaccine administered prior to adjuvant RT and chemotherapy (ClinicalTrials.gov identifier: NCT01595321). In this study, patients have had complete resections of their tumors, so RT cannot induce in situ vaccination. Furthermore, aggressive adjuvant chemotherapy may eliminate any antitumor immune response.

Combining RT and immunotherapy: logistical challenges

Timing of RT with respect to immunotherapy. The timing of RT is a function of the expected immune response at the tumor site. Because of its cytotoxic nature, administering to the tumor target could disrupt an ongoing antitumor cellular immune response. Conversely, having an active immunoadjuvant within the tumor microenvironment could maximize the effects of RT. Targeted agents such as ipilimumab could be administered prior to RT to potentiate a radiation-induced immune response; however, if ipilimumab alone is administered well before RT and has already incited an immune response at the tumor site, the cytotoxic effect of RT on lymphocytes may be detrimental. Furthermore, targeting immune checkpoints of T cell activation may be less effective if RT has not already generated de novo antigens and broken preexisting peripheral tolerance. In the case of adoptively transferred T cell immunotherapy, RT should presumably be administered prior to T cell transfer to avoid disruption of the T cell response at the tumor site.

The timing of vaccine therapy is similarly under question. Vaccine therapy is administered either systemically or intratumorally. In the latter scenario, the immune-stimulatory effects of coincident radiation may stimulate the antivaccine inflammatory response necessary for antigen presentation. Conversely, if delivered well after vaccine therapy, RT may disrupt the development of an antivaccine cellular immune response. In ongoing trials, vaccine therapy is administered either a few days prior to RT, during RT, or both. Although this has not been well studied, delivering RT well before vaccine therapy may be futile, as the vaccine may not benefit from potential transient immune-activating qualities of RT.

Fractionation of RT regimens. When priming the immune system, is it better to use conventional fractionation or hypofractionated regimens? Historically, RT has been administered in daily fractions of approximately 1.5–2.0 Gy over a period of weeks. The relatively small daily dose is designed to allow for normal tissue repair. Techniques such as intensity-modulated RT have permitted more conformal dose delivery, which more tightly matches radiation dose clouds to the shape of the tumor target and minimizes normal tissue exposure. Consequently, there has been a trend toward hypofractionation, which involves the delivery of larger daily doses in fewer fractions to achieve a high, biologically effective dose. Currently, stereotactic radiotherapy (SRT), defined as RT delivered in 5 or less fractions, is used for tumors in the brain, lung, liver, bone, and more.
Preclinical comparison studies of different fractionation regimens in combination with immunotherapy have been equivocal (69). In a mouse model of melanoma, a single dose of radiation in combination with T cell immunotherapy was more effective than a fractionated scheme (55). Conversely, in combination with TLR7 agonism, a regimen of five fractions of 2 Gy each completely eradicated tumors in a mouse model of lymphoma, while a single 10-Gy fraction only slowed growth (49). It is not clear whether the different fractionated schemes actually deliver the same biologically equivalent dose to the tumor (e.g., 20 Gy + 1 does not equal 5 Gy + 4). Furthermore, it is unclear how these fractionation schemes in animal models parallel conventional or hypofractionated RT in humans.

**Total radiation dose**

Total radiation dose is also a logistical hurdle in combining RT and immunotherapy. The goal is to provide sufficient radiation to trigger an effective antiinflammatory response and, in turn, a tumor-specific immune response. For instance, in an IFN-γ-deficient mouse model, production of IFN-γ after RT is important in switching the immune system into an antitumor position (70). IFN-γ production led to expression of molecules important for T cell homing and antigen presentation. Escalating radiation doses increased the level of IFN-γ production, although at the highest doses there was concern about a simultaneous rise in regulatory T cells (69). These early studies suggest a benefit of higher radiation doses, with the caveat of potential development of regulatory immune pathways and cells.

**Choosing a site for RT.** The degree of immune response to RT may also depend on the site of irradiation. For example, the activity of the immune system (especially dendritic cells) in the skin, gut, and lung is unique because of the exposure of these organs to external pathogens (71). Immune phenomena in the liver are different due to its chronic and persistent exposure to toxic metabolites as well as antigens from the gastrointestinal tract. The testis is an immune-privileged organ (72), and our understanding of immune phenomena in the central nervous system is evolving (73). RT may result in distinct immune phenomenon at each site. Identifying which irradiated sites best elicit a local and systemic tumor response will be critical in identifying patient groups that could maximally benefit from combined RT and immunotherapy.

**Conclusions**

The ability of RT to invoke a systemic immune response and the immune system’s role in the local effects of RT underscore the potential clinical utility of this combination approach. As ongoing trials begin to report safety and efficacy data, it will be critical to dissect this information to determine the most appropriate logistical combinations of immunotherapy and RT and to identify the patient subgroups that may benefit most from this approach.

**Acknowledgments**

The authors thank Mary Leonard for contributions to figure illustration.

Address correspondence to: Anusha Kalbasi, Hospital of the University of Pennsylvania, PCAM-4 West, 3400 Civic Center Blvd., Philadelphia, Pennsylvania 19104, USA. Phone: 215.662.2428; Fax: 215.615.1658; E-mail: Anusha.Kalbasi@uphs.upenn.edu.

---

25. Postow MA, et al. Immunologic correlates of the...


